Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors

Trial Profile

Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Ceramide (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Keystone Nano
  • Most Recent Events

    • 28 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
    • 28 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 05 Jan 2017 According to Keystone Nano media release, the U.S. Food and Drug Administration has approved the company's Investigational New Drug (IND) Application to assess Ceramide NanoLiposome in the treatment of solid tumors.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top